Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 192.7% in September

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 108,300 shares, a growth of 192.7% from the September 15th total of 37,000 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average trading volume of 222,700 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH downgraded Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 18th.

Coeptis Therapeutics Trading Up 0.9 %

Coeptis Therapeutics stock traded up $0.00 during mid-day trading on Friday, hitting $0.18. The company had a trading volume of 319,663 shares, compared to its average volume of 314,370. Coeptis Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.38. The stock’s 50 day moving average price is $0.19 and its two-hundred day moving average price is $0.27.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. As a group, equities analysts predict that Coeptis Therapeutics will post -0.26 earnings per share for the current fiscal year.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.